US equities |
MU $684.43 ▲+4.27% NVDA $186.29 ▲+2.58% AMD $438.42 ▲+8.41% SNDK $822.03 ▲+1.93% SPCX $131.48 ▲+6.36% TSLA $358.34 ▲+4.26% AAPL $344.13 ▼-0.01% MSFT $533.92 ▼-0.37%
FinancialContent

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

105.06 -17.90 (-14.56%)
Delayed Quote Updated: 1:08 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Halozyme Therapeutics, Inc. - Common Stock

News headline image
Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
News headline image
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV
From ViiV Healthcare
Via Business Wire